Merit Medical Systems Inc (MMSI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Merit Medical Systems Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 85.50 $ — 77% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
7/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 10.8%
- Exp. sales growth 3Y > 5% 7.1%
- EBIT growth 10Y > 5% 20.3%
- Exp. EBIT growth 3Y > 5% 47.3%
- Net debt < 4x EBIT 2.4x
- EBIT positive, 10Y straight 9
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% 23.8%
- ROCE > 15% 7.5%
- Expected return > 10% 53.5%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 9.6% failed
- More than 10% revenue growth is expected for the coming year 6.1% failed
- Share count grows by less than 3% a year 1.6% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 25.7% failed
- Gross margin at 40% or higher and without meaningful erosion 48.7% passed
- Goodwill from acquisitions does not grow faster than revenue 18.9% failed
- Net debt below twice EBITDA 1.4 x EBITDA passed
- Operating cash flow covers the profits of the last three years 320 m passed
- Return on capital at 15% or higher, or up versus two years ago 7.5% passed
- Insiders hold at least 10% or are net buyers 2.5% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 16.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4.30 | 4.28 – 4.32 | 1,636 | 12.3% | 10 |
| 12/31/2027 | 4.61 | 4.50 – 4.77 | 1,736 | 7.2% | 10 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.46 | -2.60 | 355 | 9.90 | 7.90 | 69 | 65 |
| 2025: Q1 | 0.49 | 2.00 | 354 | 9.50 | 8.50 | 41 | 19 |
| 2025: Q2 | 0.54 | -11.60 | 382 | 13.00 | 8.50 | 83 | 105 |
| 2025: Q3 | 0.46 | -3.00 | 384 | 13.10 | 7.20 | 75 | 52 |
| 2025: Q4 | 0.63 | 37.30 | 394 | 11.00 | 9.60 | 99 | 77 |
| 2026: Q1 | 0.68 | 38.90 | 382 | 7.90 | 10.70 | 41 | 25 |
| 2026: Q2 | 0.65 | 20.40 | 419 | 9.60 | 9.30 | 69 | 52 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 604 | 35 | 20 | 0.45 | 54 | 498 | 943 |
| 2017 | 728 | 33 | 28 | 0.55 | 63 | 676 | 1,112 |
| 2018 | 883 | 59 | 42 | 0.78 | 87 | 933 | 1,620 |
| 2019 | 995 | 15 | 5 | 0.10 | 78 | 950 | 1,757 |
| 2020 | 964 | -2 | -10 | -0.18 | 165 | 959 | 1,664 |
| 2021 | 1,075 | 61 | 48 | 0.84 | 147 | 1,040 | 1,648 |
| 2022 | 1,151 | 88 | 75 | 1.29 | 114 | 1,144 | 1,664 |
| 2023 | 1,257 | 124 | 94 | 1.62 | 145 | 1,202 | 2,325 |
| 2024 | 1,357 | 156 | 120 | 2.03 | 221 | 1,379 | 2,419 |
| 2025 | 1,515 | 184 | 128 | 2.13 | 297 | 1,584 | 2,686 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Merit Medical Systems, Inc. entwirft, entwickelt, fertigt und vermarktet Einweg-Medizinprodukte für interventionelle, diagnostische und therapeutische Verfahren in den USA, China, Japan, Deutschland, Frankreich, dem Vereinigten Königreich und international.
| Employees | 7,500 |
|---|---|
| Headquarters | South Jordan, UT |
| Address | 1600 West Merit Parkway, 84095 South Jordan, United States |
| Phone | 801 253 1600 |
| Website | merit.com |
| IPO Date | 9. Aug 1990 |
| ISIN | US5898891040 |
| Stock Split | 5:4 on 05/06/2011 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Martha Goldberg Aronson | President, CEO & Director | 1967 |
| Raul Parra Jr., CPA | CFO & Treasurer | 1979 |
| Neil W. Peterson | Chief Operating Officer | 1967 |
| Brian G. Lloyd J.D. | Chief Legal Officer & Corporate Secretary | 1961 |
| Michel J. Voigt | Chief Human Resources Officer | 1973 |
| Jason Treft | Chief Information Officer | – |
| Sarah Comstock | Vice President of Global Communications | – |
| John Knorpp | Chief Regulatory Affairs Officer | – |
| Ricardo Alvarez | Managing Director of Operation Merit Medical Tijuana | – |
| Mark Butler | Executive Vice President of Merit Medical EMEA | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.